Literature DB >> 4377543

Methyl-CCNU inclinical cancer therapy.

T H Wasserman, M Slavik, S K Carter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4377543     DOI： 10.1016/s0305-7372(74)80018-6

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

Review 1.  Systemic therapy of malignant melanoma.

Authors:  J Hansson
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.064

2.  Antitumor activity and toxicity of ACNU, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitroso urea hydrochloride, comparing two divided doses and a single dose.

Authors:  S Fujimoto; Y Wang; M Ogawa
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Cytostatic action of two nitrosoureas derived from cysteamine.

Authors:  C Bourut; E Chenu; D Godenèche; J C Madelmont; R Maral; G Mathé; G Meyniel
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

4.  Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).

Authors:  D J Straus; J Myers; B Koziner; B J Lee; B D Clarkson
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.

Authors:  R Osieka; P Glatte; R Pannenbäcker; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

7.  A new nitrosourea derivative TA-077, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea. I. Comparative study on antitumor activity.

Authors:  S Fujimoto; M Ogawa
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.